KD027 / Nano Terra, Sanofi, Retension Pharmaceuticals - LARVOL DELTA

A Study of Modified Release RTN-001 In Patients With Uncontrolled Hypertension (clinicaltrials.gov) - P2 | N=280 | Recruiting | Sponsor: Retension Pharmaceuticals. Inc. | Trial primary completion date: Oct 2026 ➔ Mar 2027

Trial primary completion date • Cardiovascular • Hypertension

Safety and Effects of SLx-2101 Taken for up to 14 Days on Blood Pressure in Patients With Hypertension (clinicaltrials.gov) - P2 | N=26 | Completed | Sponsor: Retension Pharmaceuticals. Inc. | Phase classification: P2a ➔ P2

Phase classification • Cardiovascular • Hypertension

AI-assisted identification of a novel vardenafil analog (KD-027) adulterated in capsules. (PubMed, J Forensic Sci) - "However, the increased demand for pharmacological treatments, such as sildenafil, tadalafil, and vardenafil has led to the emergence of counterfeit drugs, posing a serious public health concern. In addition, evidence of coexisting E/Z tautomerism of KD-027 was observed in the NMR data. To the best of our knowledge, this is the first report to identify KD-027 in sexual enhancement products, providing its characteristic mass spectral fragments and NMR data, and demonstrating the utility of ChatGPT-4o in forensic investigations."

Journal • Sexual Disorders

A Study of Modified Release RTN-001 In Patients With Uncontrolled Hypertension (clinicaltrials.gov) - P2 | N=280 | Recruiting | Sponsor: Retension Pharmaceuticals. Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiovascular • Hypertension

A Study of Modified Release RTN-001 In Patients With Uncontrolled Hypertension (clinicaltrials.gov) - P2 | N=280 | Not yet recruiting | Sponsor: Retension Pharmaceuticals. Inc.

New P2 trial • Cardiovascular • Hypertension

Safety and Effect of Oral Doses of 5mg or 10mg of SLx-2101 for 14 Days in Patients With Hypertension (clinicaltrials.gov) - P2 | N=38 | Completed | Sponsor: Response Pharmaceuticals | Phase classification: P2a ➔ P2

Phase classification • Cardiovascular • Hypertension

Phosphodiesterase 5 inhibitors: preclinical and early phase breakthroughs for impotence treatments. (PubMed, Expert Opin Investig Drugs) - "Our review of udenafil, mirodenafil, youkenafil, lodenafil, and SLx-2101 analyzes the safety, efficacy, and pharmacokinetic properties of these new ED drugs. It is our opinion that more robust clinical trials are required before these medications can be made available in the United States. Additionally, the field of urology may benefit from pursuing other avenues of pharmacotherapy, such as injections, tablets with a different mechanism of action, or stem cell therapy, to restore the integrity of the endothelium within the penis."

Journal • Preclinical • Review • Erectile Dysfunction • Urology

Multi-strain probiotics alleviate loperamide-induced constipation by adjusting the microbiome, serotonin, and short-chain fatty acids in rats. (PubMed, Front Microbiol) - "The abundances of the phylum Verrucomicrobia, the family Erysipelotrichaceae and the genus Akkermansia were increased in fecal samples of the probiotic-treated groups. Therefore, the multi-strain probiotics used in this experiment were thought to help alleviate LOP-induced constipation by altering the levels of short-chain fatty acids, serotonin, and mucin through improvement in the intestinal microflora."

Journal • Preclinical • Constipation • Gastroenterology • Gastrointestinal Disorder